Biology:Clostridium butyricum
| Clostridium butyricum | |
|---|---|
| |
| C. butyricum MIYAIRI 588 tablets produced by Miyarisan Pharmaceutical, Tokyo, Japan. | |
Scientific classification 
| |
| Domain: | Bacteria |
| Phylum: | Bacillota |
| Class: | Clostridia |
| Order: | Eubacteriales |
| Family: | Lachnospiraceae |
| Genus: | Clostridium |
| Species: | C. butyricum
|
| Binomial name | |
| Clostridium butyricum Prazmowski 1880 (Approved Lists 1980)
| |
Clostridium butyricum is a strictly anaerobic endospore-forming Gram-positive butyric acid–producing bacillus subsisting by means of fermentation using an intracellularly accumulated amylopectin-like α-polyglucan (granulose) as a substrate. It is uncommonly reported as a human pathogen and is widely used as a probiotic in Japan, Korea, and China.[1] C. butyricum is a soil inhabitant in various parts of the world, has been cultured from the stool of healthy children and adults, and is common in soured milk and cheeses.[2] The connection with dairy products is shown by the name, the butyr- in butyricum reflects the relevance of butyric acid in the bacteria's metabolism and the connection with Latin butyrum and Greek βούτυρον, with word roots pertaining to butter and cheese.[3]
Industrial relevance
The study of fermentation in the 19th century was of interest not only to basic science but also as applied science funded by companies in certain industries, principally winemaking and brewing, as a means to reduce risk of bad batches through greater understanding and control of the process. Thus, early microbiologists such as Louis Pasteur were funded in their research into microbial metabolism and biochemistry. Such research led to the first understanding of anaerobic metabolism,[3] and butyric acid fermentation was humans' initial window into that world.[3] In 1880, Adam Prażmowski from the University of Leipzig first assigned the binomial name Clostridium butyricum.[3][4]
Therapeutic uses
The first C. butyricum MIYAIRI strain was isolated by Dr. Chikaji Miyairi from feces in Japan in 1933.[5] In 1963, CBM 588 was isolated from a soil sample in Nagano, Japan.[5] Preparations based on CBM 588 have a long history of safe use in human populations in Japan, where such products are variously classed as pharmaceutical drugs, "quasi drugs", and OTC (Over The Counter) probiotics. The safe therapeutic use of CBM 588 in humans populations is supported by various peer-reviewed publications and case studies, including reports of CBM 588 use in severely-ill, immunocompromised, and hospitalized patients, as well as in pregnant women.[6][7][8][9]
Its usefulness stems primarily from its ability to interfere with the growth of highly pathogenic Clostridium difficile by antagonizing its multiplication.[10] It is often used in Japanese hospitals for C. difficile prophylaxis among in-patients and, particularly, during administration of certain powerful antibiotics (i.e. Levofloxacin) associated with opportunistic C. difficile infection.
CBM 588 was approved for clinical use in humans by the Japanese Ministry of Health and Welfare in 1970.[11] The standard preparation as marketed by Miyarisan Pharmaceutical (Tokyo, Japan) consists of white, marked tablets each containing 0.35 × 106 colony forming units (CFU) of C. butyricum MIYAIRI 588 (as active agent). CBM 588 does not establish permanently in the gut, in common with other orally administered probiotic bacteria. CBM 588 for clinical use is produced by submerged anaerobic fermentation followed by centrifugation, drying, blending and packaging.[9]
The MIYAIRI 588 strain of C. butyricum does not carry any genes encoding any toxins and virulence factors associated with Clostridium or other enteropathogens.[12] Absence of neurotoxin production has been demonstrated by polymerase chain reaction (PCR) and Southern blot hybridisation for type E botulinum toxin gene. The absence of genes encoding botulinum neurotoxin A,B,F and genes encoding non-toxic haemagglutinin (NTNH) and genes encoding Clostridium perfringens toxins (alpha, beta, epsilon and iota) has been demonstrated by PCR assay.
This strain is deposited at the Fermentation Research Institute, Agency of Industrial Science and Technology, Japan under the strain name Clostridium butyricum MIYAIRI 588 strain, deposit number FERM BP-2789. Recent European Food Safety Authority opinions confirm the official strain nomenclature as Clostridium butyricum FERM BP-2789.
References
- ↑ Seki, H.; Shiohara, M.; Matsumura, T.; Miyagawa, N.; Tanaka, M.; Komiyama, A.; Kurata, S. (February 2003). "Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI". Pediatrics International 45 (1): 86–90. doi:10.1046/j.1442-200x.2003.01671.x. PMID 12654076.
- ↑ Meng, X.; Karasawa, T.; Zou, K.; Kuang, X.; Wang, X.; Lu, C.; Wang, C.; Yamakawa, K et al. (August 1997). "Characterization of a neurotoxigenic Clostridium butyricum strain isolated from the food implicated in an outbreak of food-borne type E botulism". Journal of Clinical Microbiology 35 (8): 2160–2162. doi:10.1128/JCM.35.8.2160-2162.1997. PMID 9230405.
- ↑ 3.0 3.1 3.2 3.3 Newman, George (1904). Bacteriology And The Public Health. Philadelphia, Pennsylvania: P. Blakiston's Son and Co.. pp. 107–110. ISBN 9781345750270.
- ↑ Skerman, V. B. D.; McGowan, Vicki; Sneath, P. H. A. (1980). "Approved Lists of Bacterial Names". International Journal of Systematic and Evolutionary Microbiology 30 (1): 225–420. doi:10.1099/00207713-30-1-225. ISSN 1466-5034. https://www.microbiologyresearch.org/content/journal/ijsem/10.1099/00207713-30-1-225.
- ↑ 5.0 5.1 Ariyoshi, Tadashi; Hagihara, Mao; Takahashi, Motomichi; Mikamo, Hiroshige (2022). "Effect of Clostridium butyricum on Gastrointestinal Infections" (in en). Biomedicines 10 (2): 483. doi:10.3390/biomedicines10020483. ISSN 2227-9059. PMID 35203691.
- ↑ Ito, Izumi; Hayashi, Toshio; Iguchi, Akihisa; Endo, Hidetoshi; Nakao, Makoto; Kato, Koori; Nabeshima, Toshitaka; Ogura, Yozo (1997). "経管栄養施行中の高齢患者腸粘膜機能に対する酪酸菌懸濁液の効果" (in ja). 日本老年医学会雑誌 34 (4): 298–304. doi:10.3143/geriatrics.34.298. PMID 9212685. https://www.jstage.jst.go.jp/article/geriatrics1964/34/4/34_4_298/_article/-char/ja/.
- ↑ Seki, Hiromi; Shiohara, Masaaki; Matsumura, Tadao; Miyagawa, Natsuki; Tanaka, Mamoru; Komiyama, Atsushi; Kurata, Susumu (2003). "Prevention of antibiotic-associated diarrhea in children by Clostridium butyricum MIYAIRI" (in en). Pediatrics International 45 (1): 86–90. doi:10.1046/j.1442-200X.2003.01671.x. ISSN 1328-8067. PMID 12654076. https://onlinelibrary.wiley.com/doi/10.1046/j.1442-200X.2003.01671.x.
- ↑ Maebashi, Masaru; Sato, Takao; Makino, Yoshio; Furukawa, Yuji; Inomata, Tomo (1998). "Implication of 'Harmful' Intestinal Microflora in the Pathogenesis of Diseases with Immune Dysfunction". Bioscience and Microflora 17 (1): 55–60. doi:10.12938/bifidus1996.17.55. https://www.jstage.jst.go.jp/article/bifidus1996/17/1/17_1_55/_article.
- ↑ 9.0 9.1 Public Version - Clostridium butyricum MIYAIRI 588 as a novel food supplement, Advisory Committee on Novel Foods and Processes, 2012-01-31, https://acnfp.food.gov.uk/sites/default/files/mnt/drupal_data/sources/files/multimedia/pdfs/clostridiumbutyricumdossier.pdf, retrieved 2024-01-02
- ↑ Woo, TD; Oka, K; Takahashi, M; Hojo, F; Osaki, T; Hanawa, T; Kurata, S; Yonezawa, H et al. (November 2011). "Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain". Journal of Medical Microbiology 60 (11): 1617–25. doi:10.1099/jmm.0.033423-0. PMID 21700738.
- ↑ Shimbo, Izumi; Yamaguchi, Taketo; Odaka, Takeo; Nakajima, Kenichi; Koide, Akinori; Koyama, Hidehiko; Saisho, Hiromitsu (2005-12-21). "Effect of Clostridium butyricum on fecal flora in Helicobacter pylori eradication therapy". World Journal of Gastroenterology 11 (47): 7520–7524. doi:10.3748/wjg.v11.i47.7520. ISSN 1007-9327. PMID 16437727.
- ↑ "Committee Paper for Discussion: Adivosry Committee for Novel Foods and Processes - Clostridium Butyricum Probtiotic". http://www.food.gov.uk/multimedia/pdfs/acnfp10505clos.pdf.
External links
Wikidata ☰ Q2622044 entry
 |  |
